Improved treatment and monitoring for Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new way to treat and monitor Alzheimer's disease by closely tracking brain changes. It may help slow down memory loss and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your memory and thinking problems should be moderate, scoring between 16 and 25 on a standard dementia test.
- You must have had a spinal tap showing specific proteins linked to Alzheimer's.
- An MRI of your brain must show shrinking in areas typical of Alzheimer's.
- You must have had PET scans showing brain activity and protein buildup typical of Alzheimer's.
- You must not have serious health issues like active cancer, severe heart disease, or advanced liver or kidney problems.
- You should not be on insulin for diabetes or have conditions like schizophrenia or severe epilepsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an oral (taken by mouth) medication called semaglutide can slow the progression of Alzheimer's disease. Semaglutide is already used for diabetes and weight management, and this trial looks at its potential effect on memory and thinking.
This study tests whether two drugs—IL-2 (an immune-boosting medication) and semaglutide (a diabetes drug that may help brain function)—can slow memory loss in people with Alzheimer's disease. Researchers believe these drugs together might help reduce brain inflammation and protect memory.
This study tests if a combination of insulin and semaglutide (a diabetes drug) can improve memory and thinking in people with mild cognitive impairment (MCI) who also have metabolic syndrome (a cluster of health issues like large waist, high blood sugar, and high blood pressure). It aims to see if treating blood sugar problems helps protect the brain.
This study tracks the safety and effectiveness of Rybelsus (oral semaglutide) in people with type 2 diabetes who are starting the medication as part of their usual care. It helps confirm that the drug works well and is safe in everyday practice.
This study tests whether an oral medication called semaglutide can help people with type 2 diabetes, fatty liver, and kidney problems. It aims to see if it can improve kidney function and liver health.
This trial tests whether semaglutide changes blood flow in the brain and the brain’s “barrier” (how well the brain is protected) in people with type 2 diabetes. It may help researchers understand brain-related effects of diabetes treatment using scans and blood tests.
Hear when a new Alzheimer Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.